Clinical Trial NU MD11C03
- BTTC11-01: Randomized, Double-Blind, Placebo-Controlled Trial of Lacosamide for Seizure Prophylaxis in Patients with High-Grade Gliomas
- Principal Investigator
- Jeffrey Raizer
- Status: COMPLETED
- Study Type: Supportive Care, Treatment
- Protocol No:.NU MD11C03
- This is a randomized double-blind study is to test if the drug Lacosamide, an antiepileptic (anti-seizure)medication,can prevent seizures in patients who have had surgery for a brain cancer called malignant glioma.
- This study is for patients who have had surgery for a brain cancer called malignant glioma. To date there have not been any definitive studies to determine the potential benefit of using anti-seizure medication to prevent seizures in at risk patients who have not yet had a seizure. Brain cancer patients who have undergone surgery for are at risk for seizures. This double-blind placebo study will assess the effectiveness of using Lacosamide, an FDA approved and commercially available anti-seizure drug, as a preventive medication to reduce the risk of seizures.
Some of the eligibility criteria include:
- Patients must have diagnosis of high-grade glioma.
- Patients must be 18 years of age or older.
- Patients must not have a history of any type of seizure for at least 10 years prior to registration.
- Description of Treatment
- Participants in this study will take the study drug every day for up to a year, unless the doctor asks the participant to stop taking the drug earlier for safety concerns.
- Sara Duffey
Clinical Research and Education Specialist
Robert H. Lurie Comprehensive Cancer Center
Find Related Clinical Trials
Browse by Disease Sites
last updated: 29-Aug-16 11:56 PM
Clinical trial availability changes frequently. Please check this site often for updates or call 312.695.1102 for personal assistance.